Prior Surgical Resection and Ga-68-DOTANOC PET/CT Imaging-Based Parameters: Do These Impact Outcomes in Grade II Gastroentero-Pancreatic Neuroendocrine Tumors (GEP-NETs) Abstract #2935

Introduction: Grade 2 GEP-NETs have inherent tumor heterogeneity seen with positive expression of somatostatin (SSTR) and glucose (GLUT) receptors. Prior surgical resection and imaging parameters on Ga-68 DOTANOC PET/C are well-established variable impacting prognosis in well-differentiated grade 1 NETs. Since the degree of differentiation is variable in Grade 2 NETs, these parameters have not been studied.
Aim(s): To evaluate prognostic role of prior surgical resection and Ga 68 DOTANOC PETCT parameters in patients with grade II GEP-NETs.
Materials and methods: We included 85 patients with WHO grade II GEP- NET who underwent Ga-68 DOTANOC PETCT. In 46/85 patients, surgical resection of primary was performed. Patients were stratified into 2 groups based on SUVmax of target lesion, liver involvement on DOTANOC PET and surgical resection of primary. Progression free survival was calculated from the date of DOTANOC PETCT done to last date of clinical/ radiological progression or death due to disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Ameya Puranik

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2951 Analysis of Discordance between Biopsy Grade and Surgical Pathology Grade in Resected PanNEN Patients
Introduction: In PanNEN cases, treatment strategies are decided by tumor localization, volume and grade. In unresectable or metastatic cases, tumor grade is determined by biopsy specimen obtained from EUS-FNA and diagnostic accuracy of biopsy according to WHO classification 2017 is important for decision making of treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Kenzo Nakano
Authors: Nakano K, Masui T, Yogo A, Uchida Y, ...
#2161 Outcomes of Locoregional Treatment for Unifocal Progression in Widespread Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Taymeyah Al-Toubah
Authors: Al-Toubah T, Cives M, Anaya D, Soares H, ...
#1848 Liver Metastatic Disease (LMD) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Incidence, Treatment and Survival in a Multicenter Study in Argentina. Preliminary Report. ARGENTUM GROUP
Introduction: The first observational Study from our Group in Argentina, showed 60% incidence of liver mets at initial diagnosis. The treatment encompasses a wide scope of surgical and non-surgical modalities.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Juan Manuel O'Connor
Keywords: Liver, NETs
#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#2104 Direct Cost of Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Relation to Time Since Diagnosis Shows Growing Importance of Somatostatin Analogues (SSA)
Introduction: Metastatic GEP-NET G1/G2 incurs large costs on the Swedish health care system.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Daniel Granfeldt